Cancer Research
The promise of immuno-oncology in the neoadjuvant setting
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
The promises of antibody-drug conjugates for ovarian cancer
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
A phase I study shows a promising strategy to overcome resistance to immunotherapy in cancer
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Locally advanced gastrointestinal cancers: moving forward in the neoadjuvant setting
Recent results from research have changed the treatment paradigm for some digestive tumours, but further evidence is needed to finetune the neoadjuvant approach
When to perform next-generation sequencing test in patients with cancer? ESMO updates its recommendations
NGS testing is now recommended also for patients with some rare tumours and to detect tumour-agnostic alterations
Breast cancer research: lessons learnt from the past will shape the future
In her key lecture, the 2024 ESMO Breast Cancer Awardee Prof. Hope S. Rugo reflects on the current challenges in the field
New insights into the evolutionary pattern of breast cancer
A more detailed picture of breast cancer establishment may facilitate prevention and detection in women at high risk
Making personalised precision medicine a reality for early breast cancer
Individualised assessment of initial response to therapy may pave the way for chemotherapy-sparing treatment, but it requires that multidisciplinary teams adapt their current practices
Extending the continuum of care for metastatic colorectal cancer
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib